ARBUTUS BIOPHARMA CORPORATION

ABUS

CIK 0001447028 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$1M
↓-33.2% -$523Kvs FY2024 (Q4)
Gross Profit
$1M
↓-33.2% -$523Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
50/100
  • Profitability
    0ROIC -43.9% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 15.73 (above 1.5 = solid)
  • Leverage
    100D/E 0.00 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.12x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -33.2% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -1636.9% · trend +345.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$0
investment in PP&E
Stock-based comp (TTM)
$7M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$95M
everything owned
Total liabilities
$18M
everything owed
Stockholders' equity
$77M
shareholder claim
Net debt
$-18M
Net cash position ($18M)

Recent performance · 54 quarters

Revenue↓-33.2% -$523K
$1M
Net Income↑+60.7% +$12M
$-8M
Free Cash Flow↑+100.0% +$86K
$0
Operating Margin↓-35.7pts
-1636.9%

Drill down